Future studies should validate these findings in animal models and further evaluate the long-term effects of C3G therapy on glucose homeostasis and insulin sensitivity, as well as the potential side effects of long-term use of C3G
PLoS ONE 11 , e0150108 (2016)
ELIXA trial included patients with recent cardiovascular event (patients with acute coronary syndrome 180 days before randomization), and although there was no benefit in MACE reduction in lixisenatide treated patients compared to placebo, results revealed cardiovascular safety of lixisenatide in this specific high risk population ( Dose-dependent effect for oral semaglutide was assessed and proven in Japanese PIONEER 9 trial, where greater reduction of HbA1c and weight loss was achieved with higher dose of oral semaglutide compared to placebo and 0.9 mg liraglutide ( Mechanisms related to cardiovascular effects of GLP-1 receptor agonists The cardiovascular effects of GLP-1 receptor agonists in CVOTs can be attributed to several mechanisms
Specifically, it is a 39-amino-acid chain with a synthetic modification: a C20 fatty diacid moiety attached via a linker to the lysine residue at position 20
Set realistic expectations: GLP-1 medications are valuable tools for weight management, but they are not quick fixes
If you become pregnant while using Wegovy, you may want to consider signing up for this medications pregnancy exposure registry, which collects information about you and your baby, helping healthcare providers and consumers know more about how certain medications can affect pregnancy